SHANGRI-LA COUNTY, China, Aug. 22, 2011 /PRNewswire/ -- Tibet Pharmaceuticals, Inc. (NASDAQ: TBET), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today announced the release of an in-depth research report update by Patrick Murphy, CFA, principal of fee-based, third-party research firm Murphy Analytics.
In his report, Mr. Murphy discusses Tibet Pharmaceuticals’ business and current portfolio of five traditional Tibetan medicine products, outlines recent developments and states that Tibet is trading at less than cash value.
“Through our strong growth initiatives and portfolio of five SFDA-approved medicines, Tibet Pharmaceuticals is addressing the increasing demand for pharmaceutical and healthcare products in China,” said Hong Yu, CEO and Chairman of Tibet Pharmaceuticals. “This research report update provides investors with an in-depth analysis of Tibet’s particular strengths in the Traditional Chinese Medicine, or TCM, market in China and delivers a comprehensive overview of our recently reported revenue and earnings as we seek to continue to drive growth in 2011.”
This research report update provides investors with a current analysis of the growth of the Chinese pharmaceutical market, and delivers a comprehensive overview of Tibet Pharmaceuticals’ recently-reported revenue and earnings. Murphy Analytics also explains that despite Tibet Pharmaceuticals’ revenue growth, its current valuation multiple is lower than many of its peers.
In his updated report, Mr. Murphy states, “Various benchmark indices, with varying degrees of relevance for TBET operations, are trading at price / earnings multiples ranging from 12.6x to 20.5x. A smaller sampling of publicly traded stocks generally operating in the Chinese healthcare / pharmaceutical sector is trading at an average P/E multiple of 5.3x, while TBET is trading at less than half the multiple for this sampling and generally in line with peers that are struggling rather than reporting earnings and revenue growth like TBET.”
“At a recent market cap of $26.7 million, TBET is trading at less than the $29.5 in cash and cash equivalents reported as of 6/30/11,” concludes Mr. Murphy.
The complete report, which was commissioned by Tibet Pharmaceuticals, Inc., is available in Acrobat format, free of charge: http://www.murphyanalytics.com/uploads/TBET_Update.pdf
About Tibet Pharmaceuticals, Inc.
Based in Shangri-La County, Yunnan Province, China, Tibet Pharmaceuticals, Inc. (NASDAQ: TBET) is a rapidly growing specialty pharmaceutical company engaged in the research, development, manufacturing and marketing of modernized traditional Tibetan medicines in China. With over 190 employees and nation-wide distributors, the company develops both prescription and over-the-counter traditional Tibetan medicines that promote health in human respiratory, digestive, urinary and reproductive systems. Tibet Pharmaceuticals’ products are sold throughout China, with a majority of sales concentrated in the southern provinces, most notably Yunnan Province, where the company’s 52,000 sq. ft. GMP-certified manufacturing facilities are located. The access to key raw materials, not generally available outside the province, provides a significant advantage for Tibet Pharmaceuticals.
For comprehensive investor relations material, including fact sheets, research reports, presentations and video, please follow the appropriate link: Research Report, Investor Portal and Overview Video.
For more information on Tibet Pharmaceuticals, please visit: www.tibetpharmaceuticals.com
Information Regarding the Murphy Analytics Report
SEC Section 17(b) Disclosure: Murphy Analytics has been paid $3,000 by Tibet Pharmaceuticals, Inc. Although the Murphy Analytics report described herein was commissioned and paid for by Tibet Pharmaceuticals, Inc., the company notes that the report was generated independently by Mr. Murphy, and statements by Mr. Murphy are his own and not attributable to Tibet Pharmaceuticals, Inc. Readers are advised to review the report in its entirety, including the disclosures and disclaimers noted therein.
Forward-Looking Statements
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. Specifically, references herein to contemplated growth in company revenues and/or earnings or expected company valuations are forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, changes in company valuations and investor perceptions of companies, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In particular, the company advises investors that the company commissioned the research report discussed in this press release. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
Financial Communications Contact:
Trilogy Capital Partners - Asia
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com
SOURCE Tibet Pharmaceuticals, Inc.
